|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
CCM Duopharma Biotech Berhad
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name CCM Duopharma Biotech Berhad Headquarters Lot 2599 Jalan Seruling 59, Kawasan 3, Taman Klang Jaya; Klang; Selangor; 41200 Legal Address Level 13, Menara PNB, 201-A Jalan Tun Razak; Kuala Lumpur; Wilayah Persekutuan; 50400 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational ISIN CODE : MYL7148OO009 Financial Auditors: KPMG (2011) Incorporation Date: August 23, 2000 Total Employees: 425 Tel: (60 3) 33232759 |
|
Company Description |
|
The Company is principally engaged in investment holding, whilst the principal activities of the subsidiary are manufacturing, distributing, importing and exporting of ¶pharmaceutical products and medicines. CCM Duopharma Biotec Berhad (formely known as Duopharma Biotech Berhad) (CCMDBIO) was incorporated in Malaysia under the companies act on 23 August 2000 as a public limited company. It was listed on the Main Board of the Bursa Malaysia on 18 July 2002. It is a shariah approved security |
||
|
||
Company Analysis |
| According to the Consolidated - Non-Audited financial statement for the first three cumulated quarters of 2012, total net operating revenues decreased with -5.36%, from MYR 105,597 thousands to MYR 99,932 thousands. Operating result decreased from MYR 27,024 thousands to MYR 26,931 thousands which means -0.34% change. The results of the period decreased -1.77% reaching MYR 20,017 thousands at the end of the period against MYR 20,377 thousands last year. Return on equity (Net income/Total equity) went from 12.50% to 11.82%, the Return On Asset (Net income / Total Asset) went from 10.35% to 10.24% and the Net Profit Margin (Net Income/Net Sales) went from 19.30% to 20.03% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 15.45% compared to 20.80% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 3.78 to 4.43 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 Q3C (cons) |
2012 Q2C (cons) |
|
 | ||
| Non-Audited | Non-Audited | |
| ||
| WVB Company Financials | WVB Company Financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
195,539 |
197,931 |
| ||
Current Assets |
93,140 |
94,283 |
| ||
Total Liabilities |
26,174 |
35,008 |
| ||
Shareholders Equity |
169,365 |
162,923 |
| ||
Current Liabilities |
21,022 |
29,856 |
| ||
| * All the accounts are in MYR. | ||
Income Statement
| ||
Total Operating Revenue |
99,932 |
71,001 |
| ||
Operational Profit (Loss) |
26,931 |
18,069 |
| ||
Net Profit (Loss) |
20,017 |
13,575 |
| ||
| * All the accounts are in MYR. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
10.24% |
6.86% |
| ||
Annualised Return on Assets (ROA) |
13.65% |
13.72% |
| ||
Return on Equity (ROE) |
11.82% |
8.33% |
| ||
Annualised Return on Equity (ROE) |
15.76% |
16.66% |
| ||
Return on Sales (ROS) |
20.03% |
19.28% |
| ||
Return on Capital |
11.82% |
8.33% |
| ||
Gross Profit Margin |
51.17% |
50.64% |
| ||
Operating Profit Margin |
31.44% |
29.58% |
| Efficiency Ratios | ||
| ||
Accounts Receivable Turnover |
2.75x |
1.82x |
| ||
Inventory Turnover |
1.03x |
0.74x |
| ||
Current asset turnover |
1.07x |
0.75x |
| ||
Fixed-asset turnover |
0.98x |
0.68x |
| ||
Asset Turnover |
0.51x |
0.36x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
26,320 |
18,069 |
| ||
EBITDA |
31,416 |
21,416 |
| ||
Enterprise value |
328,559 |
315,441 |
| ||
Enterprise Value / EBITDA |
10.46 |
14.73 |
| ||
Bookvalue (BV) |
191,374 |
191,683 |
| ||
Net Cash |
-16,245 |
-28,010 |
| Liquidity Ratios | ||
| ||
Current Ratio |
443.06% |
315.79% |
| ||
Quick ratio |
216.83% |
159.05% |
| ||
Doom's day ratio |
22.72% |
6.18% |
| Leverage Ratios | ||
| ||
Leverage ratio |
115.45% |
121.49% |
| ||
Interest Coverage Ratio |
10,045.8% |
7,285.89% |
| ||
Debt to equity |
15.45% |
21.49% |
| ||
Debt to total assets |
13.39% |
17.69% |
| ||
Long Term Debt to Capital |
6.88% |
6.88% |
| ||
Debt / Enterprise Value |
1.27% |
1.98% |
| Market ratios | ||
| ||
Market Capitalization/EBITDA |
10.48 |
14.52 |
| ||
Price/Book Ratio |
1.75 |
1.60 |
| ||
Market Cap / Net cash |
-20.26 |
-11.10 |
| Trend Ratios | ||
| ||
Revenue Trend |
95.09% |
103.05% |
| ||
Net Income Trend |
98.23% |
104.26% |
| ||
Operating Income Trend |
97.39% |
105.13% |
| ||
 |